Both pirfenidone and nintedanib, approved for IPF, inhibit key fibrotic signaling cascades, including TGF-β pathways, oxidative stress responses, and fibroblast proliferation. This evidence concerns the gene TGFB1 and idiopathic interstitial pneumonia.